199 related articles for article (PubMed ID: 19570961)
1. Response to imatinib plus sirolimus in advanced chordoma.
Stacchiotti S; Marrari A; Tamborini E; Palassini E; Virdis E; Messina A; Crippa F; Morosi C; Gronchi A; Pilotti S; Casali PG
Ann Oncol; 2009 Nov; 20(11):1886-94. PubMed ID: 19570961
[TBL] [Abstract][Full Text] [Related]
2. Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study.
Stacchiotti S; Morosi C; Lo Vullo S; Casale A; Palassini E; Frezza AM; Dinoi G; Messina A; Gronchi A; Cavalleri A; Venturelli E; Morelli D; Pilotti S; Collini P; Brich S; Tamborini E; Mariani L; Casali PG
Cancer; 2018 Oct; 124(20):4056-4063. PubMed ID: 30216418
[TBL] [Abstract][Full Text] [Related]
3. A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours.
Adenis A; Ray-Coquard I; Italiano A; Chauzit E; Bui-Nguyen B; Blay JY; Tresch-Bruneel E; Fournier C; Clisant S; Amela EY; Cassier PA; Molimard M; Penel N
Br J Cancer; 2013 Nov; 109(10):2574-8. PubMed ID: 24149182
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of imatinib in advanced chordoma.
Stacchiotti S; Longhi A; Ferraresi V; Grignani G; Comandone A; Stupp R; Bertuzzi A; Tamborini E; Pilotti S; Messina A; Spreafico C; Gronchi A; Amore P; Vinaccia V; Casali PG
J Clin Oncol; 2012 Mar; 30(9):914-20. PubMed ID: 22331945
[TBL] [Abstract][Full Text] [Related]
5. Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Lebellec L; Chauffert B; Blay JY; Le Cesne A; Chevreau C; Bompas E; Bertucci F; Cupissol D; Fabbro M; Saada-Bouzid E; Duffaud F; Feuvret L; Bonneville-Levard A; Bay JO; Vauleon E; Vinceneux A; Noel G; Penel N; Mir O
Eur J Cancer; 2017 Jul; 79():119-128. PubMed ID: 28478340
[TBL] [Abstract][Full Text] [Related]
6. Phase II study on lapatinib in advanced EGFR-positive chordoma.
Stacchiotti S; Tamborini E; Lo Vullo S; Bozzi F; Messina A; Morosi C; Casale A; Crippa F; Conca E; Negri T; Palassini E; Marrari A; Palmerini E; Mariani L; Gronchi A; Pilotti S; Casali PG
Ann Oncol; 2013 Jul; 24(7):1931-1936. PubMed ID: 23559153
[TBL] [Abstract][Full Text] [Related]
7. Imatinib in advanced chordoma: A retrospective case series analysis.
Hindi N; Casali PG; Morosi C; Messina A; Palassini E; Pilotti S; Tamborini E; Radaelli S; Gronchi A; Stacchiotti S
Eur J Cancer; 2015 Nov; 51(17):2609-14. PubMed ID: 26283036
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate in chordoma.
Casali PG; Messina A; Stacchiotti S; Tamborini E; Crippa F; Gronchi A; Orlandi R; Ripamonti C; Spreafico C; Bertieri R; Bertulli R; Colecchia M; Fumagalli E; Greco A; Grosso F; Olmi P; Pierotti MA; Pilotti S
Cancer; 2004 Nov; 101(9):2086-97. PubMed ID: 15372471
[TBL] [Abstract][Full Text] [Related]
9. Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.
Katz D; Azraq Y; Eleyan F; Gill S; Peretz T; Merimsky O
BMC Cancer; 2016 Aug; 16():616. PubMed ID: 27501793
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review.
Launay SG; Chetaille B; Medina F; Perrot D; Nazarian S; Guiramand J; Moureau-Zabotto L; Bertucci F
BMC Cancer; 2011 Oct; 11():423. PubMed ID: 21970335
[TBL] [Abstract][Full Text] [Related]
11. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
12. Chordoma: a case series and review of the literature.
Alan O; Akin Telli T; Ercelep O; Tanrikulu Simsek E; Basoglu Tuylu T; Mutis A; Hasanov R; Kaya S; Akgül Babacan N; Dane F; Yumuk PF
J Med Case Rep; 2018 Aug; 12(1):239. PubMed ID: 30145982
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin.
Ricci-Vitiani L; Runci D; D'Alessandris QG; Cenci T; Martini M; Bianchi F; Maira G; Stancato L; De Maria R; Larocca LM; Pallini R
Neoplasia; 2013 Jul; 15(7):773-82. PubMed ID: 23814489
[TBL] [Abstract][Full Text] [Related]
14. A small prospective study of chordomas treated with radiotherapy and razoxane.
Rhomberg W; Böhler FK; Novak H; Dertinger S; Breitfellner G
Strahlenther Onkol; 2003 Apr; 179(4):249-53. PubMed ID: 12707714
[TBL] [Abstract][Full Text] [Related]
15. Chordoma. Cytomorphologic findings in 14 cases diagnosed by fine needle aspiration.
Kay PA; Nascimento AG; Unni KK; Salomão DR
Acta Cytol; 2003; 47(2):202-8. PubMed ID: 12685190
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
17. Chordoma.
Casali PG; Stacchiotti S; Sangalli C; Olmi P; Gronchi A
Curr Opin Oncol; 2007 Jul; 19(4):367-70. PubMed ID: 17545801
[TBL] [Abstract][Full Text] [Related]
18. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
19. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.
Maurel J; Martins AS; Poveda A; López-Guerrero JA; Cubedo R; Casado A; Martínez-Trufero J; Ramón Ayuso J; Lopez-Pousa A; Garcia-Albeniz X; Garcia del Muro X; de Alava E
Cancer; 2010 Aug; 116(15):3692-701. PubMed ID: 20564079
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chordoma with imatinib complicated by intracranial hemorrhage: a case showing dissociation between biological effect and therapeutic outcome.
Mercier F; Guiot MC; Bojanowski MW
J Neurooncol; 2012 Apr; 107(2):435-7. PubMed ID: 22120582
[No Abstract] [Full Text] [Related]
[Next] [New Search]
